Table 1.
Trial | Phase | Setting | Patients | Targeted agent | DCR |
Cooney et al[38] | II | Advanced pretreated disease | 18 with ATC | CA4P alone | 33% |
Cohen et al[46] | II | Advanced pretreated disease | 60 (2 with ATC) | Axitinib alone | 71% |
Ha et al[53] | II | Advanced pretreated disease | 11 with ATC | Imatinib alone | 75% |
Nagaiah et al[54] | II | Advanced pretreated disease | 16 with ATC | Sorafenib alone | 40% |
ATC: Anaplastic thyroid carcinoma; CA4P: Combretastatin A4; DCR: Disease control rate (complete responses + partial responses + stable disease).